Locoregional Therapies for Hepatocellular Carcinoma: What Has Changed in the Past Ten Years?

Anjana A. Pillai, Meera Ramanathan, Laura Kulik*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Abstract

The evolution of locoregional therapies in the last decade has been refined with improved patient selection and a development of a more personalized approach. In doing so, there has been associated improved outcomes and less toxicity. With the rapidly changing landscape of systemic therapy, the role of locoregional therapies alone or in combination for downstaging and curative intent will continue to evolve.

Original languageEnglish (US)
Pages (from-to)681-700
Number of pages20
JournalClinics in liver disease
Volume24
Issue number4
DOIs
StatePublished - Nov 2020

Keywords

  • HCC
  • Liver cancer
  • Locoregional therapy
  • Systemic therapy
  • TACE
  • TARE
  • Y90

ASJC Scopus subject areas

  • Hepatology

Fingerprint

Dive into the research topics of 'Locoregional Therapies for Hepatocellular Carcinoma: What Has Changed in the Past Ten Years?'. Together they form a unique fingerprint.

Cite this